Connecticut moves to expand psychedelic-assisted therapy study for PTSD, depression
Connecticut legislators have passed a bill to expand a state-authorized program testing psychedelic-assisted therapy for treating mental health conditions, including PTSD and depression. The bill, which awaits Gov. Ned Lamont's signature, would open the pilot program to patients aged 18 and older and remove a sunset clause tied to FDA approval of MDMA and psilocybin.
Connecticut legislators have passed a bill to expand a state-authorized program testing psychedelic-assisted therapy for mental health conditions. The program, established in 2022, initially limited enrollment to Connecticut veterans, retired first responders, and direct healthcare workers. The new legislation would open it to qualifying patients aged 18 and older. The bill also removes a requirement that the program terminate if the US Drug Enforcement Agency approves MDMA and psilocybin for medical use. The state Department of Mental Health and Addiction Services partnered with Yale School of Medicine to provide the treatment. Gov. Ned Lamont is expected to sign the bill into law.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.